These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 23300363

  • 1. Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma.
    Delea TE, El Ouagari K, Rotter J, Wang A, Kaura S, Morgan GJ.
    Curr Oncol; 2012 Dec; 19(6):e392-403. PubMed ID: 23300363
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective.
    Delea TE, Rotter J, Taylor M, Chandiwana D, Bains M, El Ouagari K, Kaura S, Morgan GJ.
    J Med Econ; 2012 Dec; 15(3):454-64. PubMed ID: 22316275
    [Abstract] [Full Text] [Related]

  • 3. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
    Raje N, Roodman GD, Willenbacher W, Shimizu K, García-Sanz R, Terpos E, Kennedy L, Sabatelli L, Intorcia M, Hechmati G.
    J Med Econ; 2018 May; 21(5):525-536. PubMed ID: 29480139
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [Abstract] [Full Text] [Related]

  • 6. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K, Plosker GL.
    Pharmacoeconomics; 2008 Oct; 26(3):251-68. PubMed ID: 18282018
    [Abstract] [Full Text] [Related]

  • 7. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
    Snedecor SJ, Carter JA, Kaura S, Botteman MF.
    Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.
    Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Wu P, Davies FE, National Cancer Research Institute Haematological Oncology Clinical Studies Group.
    Lancet Oncol; 2011 Aug; 12(8):743-52. PubMed ID: 21771568
    [Abstract] [Full Text] [Related]

  • 16. Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.
    Ford J, Cummins E, Sharma P, Elders A, Stewart F, Johnston R, Royle P, Jones R, Mulatero C, Todd R, Mowatt G.
    Health Technol Assess; 2013 Jul; 17(29):1-386. PubMed ID: 23870108
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
    Jakubowiak AJ, Campioni M, Benedict Á, Houisse I, Tichy E, Giannopoulou A, Aggarwal SK, Barber BL, Panjabi S.
    J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of single-dose zoledronic acid for nursing home residents with osteoporosis in the USA.
    Ito K.
    BMJ Open; 2018 Sep 04; 8(9):e022585. PubMed ID: 30181186
    [Abstract] [Full Text] [Related]

  • 19. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.
    Health Technol Assess; 2007 Nov 04; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [Abstract] [Full Text] [Related]

  • 20. Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.
    Zeng X, Liu Q, Peng L, Peng Y, Yi L, Luo X, Li S, Wan X, Tan C.
    Adv Ther; 2021 May 04; 38(5):2379-2390. PubMed ID: 33770365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.